Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Growth Officer | November 07, 2023 | November 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date November 07, 2023 · Filed November 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 124,511 |
Reported balance
After 2023-11-07 transaction · row 1
1 source rowRow 1 · 2023-11-07 · Sale · Disposed 382 · Balance 124,511 F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2019 Filed Jul 30, 2019 19:57 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,455 | $78.68 | $193,149.58 |
DisclosureSEC source: 0001209191-19-043642 · doc4.xml · nonDerivative · entry 5 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,933 F5 · price: On July 26, 2019, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, he sold these shares in multiple trades at prices ranging from $77.94 to $78.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 19:57 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,800 | $77.28 | $216,375.60 |
DisclosureSEC source: 0001209191-19-043642 · doc4.xml · nonDerivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,388 F4 · price: On July 26, 2019, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, he sold these shares in multiple trades at prices ranging from $76.88 to $77.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 19:57 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,710 | $76.39 | $207,016.90 |
DisclosureSEC source: 0001209191-19-043642 · doc4.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,188 F3 · price: On July 26, 2019, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, he sold these shares in multiple trades at prices ranging from $75.86 to $76.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 19:57 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 578 | $75.04 | $43,371.96 |
DisclosureSEC source: 0001209191-19-043642 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,898 F2 · price: On July 26, 2019, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, he sold these shares in multiple trades at prices ranging from $74.80 to $75.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 19:57 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 12,500 | $19.25 | $240,625.00 |
DisclosureSEC source: 0001209191-19-043642 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 14:47 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,500 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-19-042854 · doc4.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Ordinary Shares · 7,500 shares Expires 2028-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 14:47 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,500 | $70.00 | $525,000.00 |
DisclosureSEC source: 0001209191-19-042854 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,976 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 14:47 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,500 | $27.60 | $207,000.00 |
DisclosureSEC source: 0001209191-19-042854 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 764 | $27.81 | $21,248.37 |
DisclosureSEC source: 0001209191-19-041560 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,976 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2019 through June 30, 2019. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2019. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 22:55 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,175 | $60.30 | $673,852.50 |
DisclosureSEC source: 0001209191-19-039541 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,037 F1 · price: On June 27, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 11,175 shares in multiple trades at prices ranging from $60.02 to $60.97. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:06 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $11.85 | $0.00 |
DisclosureSEC source: 0001209191-19-038457 · doc4.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 12,500 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:06 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 12,500 | $60.00 | $750,000.00 |
DisclosureSEC source: 0001209191-19-038457 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,212 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:06 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 12,500 | $11.85 | $148,125.00 |
DisclosureSEC source: 0001209191-19-038457 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 60 | $55.60 | $3,336.00 |
DisclosureSEC source: 0001209191-19-036352 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,212 F2 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,070 | $55.02 | $58,875.68 |
DisclosureSEC source: 0001209191-19-036352 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,272 F1 · price: On June 10, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 1,070 shares in multiple trades at prices ranging from $54.60 to $55.50. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028889 · doc4.xml · derivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F2 · derivative.expiration_date: Options to buy 20,000 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $71.34 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Shah has been continuously employed by the Company through May 8, 2022. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 33,052 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028889 · doc4.xml · derivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,052 Underlying: Ordinary Shares · 33,052 shares Expires not disclosed F1 · derivative.expiration_date: Options to buy 33,052 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $59.45 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Shah has been continuously employed by the Company through May 8, 2022. Read SEC document |
| May 02, 2019 Filed May 3, 2019 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,204 | $43.80 | $52,729.18 |
DisclosureSEC source: 0001209191-19-027333 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,342 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 2,334 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-027333 · doc4.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Underlying: Ordinary Shares · 2,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,334 | $44.07 | $102,859.38 |
DisclosureSEC source: 0001209191-19-027333 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 8,869 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001209191-19-021969 · doc4.xml · derivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,869 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 23,652 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001209191-19-021969 · doc4.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 23,652 shares Expires 2022-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 8,869 | $7.03 | $62,349.07 |
DisclosureSEC source: 0001209191-19-021969 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 23,652 | $6.72 | $158,941.44 |
DisclosureSEC source: 0001209191-19-021969 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 20:23 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 33,783 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001209191-19-021323 · doc4.xml · derivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,783 Underlying: Ordinary Shares · 33,783 shares Expires 2029-03-21 F2 · derivative.exercise_date: Options to buy 33,783 ordinary shares will vest and become exercisable in equal installments on each of March 5, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 20:23 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 18,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021323 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,691 F1 · shares: Represents restricted share units that are scheduled to vest on March 5, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 16,897 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · derivative · entry 12 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,961 Underlying: Ordinary Shares · 16,897 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 16,250 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · derivative · entry 11 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,514 Underlying: Ordinary Shares · 16,250 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,439 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · derivative · entry 10 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24 Underlying: Ordinary Shares · 7,439 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,736 | $56.09 | $433,943.18 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · nonDerivative · entry 9 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,239 F7 · price: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 7,736 shares in multiple trades at prices ranging from $55.62 to $56.57. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,161 | $55.23 | $505,989.51 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · nonDerivative · entry 8 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,975 F6 · price: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 9,161 shares in multiple trades at prices ranging from $54.62 to $55.61. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 16,897 | $21.15 | $357,371.55 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · nonDerivative · entry 7 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,517 | $56.10 | $421,681.15 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · nonDerivative · entry 6 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,239 F5 · price: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 7,517 shares in multiple trades at prices ranging from $55.62 to $56.56. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,733 | $55.23 | $482,297.39 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · nonDerivative · entry 5 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,756 F4 · price: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 8,733 shares in multiple trades at prices ranging from $54.62 to $55.61. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 16,250 | $7.15 | $116,187.50 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · nonDerivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,312 | $56.11 | $185,839.63 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,239 F3 · price: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 3,312 shares in multiple trades at prices ranging from $55.72 to $56.55. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,127 | $55.23 | $227,946.59 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,551 F2 · price: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 4,127 shares in multiple trades at prices ranging from $54.64 to $55.61. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,439 | $11.46 | $85,250.94 |
DisclosureSEC source: 0001209191-19-015550 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,558 | $53.68 | $83,633.44 |
DisclosureSEC source: 0001209191-19-014996 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,239 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 3,087 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014996 · doc4.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,172 Underlying: Ordinary Shares · 3,087 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,087 | $52.90 | $163,302.30 |
DisclosureSEC source: 0001209191-19-014996 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 22:56 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,377 | $53.63 | $341,985.76 |
DisclosureSEC source: 0001209191-19-013679 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,710 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:56 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 13,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013679 · doc4.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,999 Underlying: Ordinary Shares · 13,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:56 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 13,000 | $53.38 | $693,940.00 |
DisclosureSEC source: 0001209191-19-013679 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $19.25 | $0.00 |
DisclosureSEC source: 0001209191-19-004551 · doc4.xml · derivative · entry 6 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Ordinary Shares · 12,500 shares Expires 2027-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $11.85 | $0.00 |
DisclosureSEC source: 0001209191-19-004551 · doc4.xml · derivative · entry 5 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Ordinary Shares · 12,500 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 12,500 | $45.00 | $562,537.50 |
DisclosureSEC source: 0001209191-19-004551 · doc4.xml · nonDerivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,087 F3 · price: On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 12,500 shares in multiple trades at prices ranging from $45.00 to $45.03. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 12,500 | $19.25 | $240,625.00 |
DisclosureSEC source: 0001209191-19-004551 · doc4.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 12,500 | $45.00 | $562,537.50 |
DisclosureSEC source: 0001209191-19-004551 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,087 F2 · price: On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 12,500 shares in multiple trades at prices ranging from $45.00 to $45.03. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 12,500 | $11.85 | $148,125.00 |
DisclosureSEC source: 0001209191-19-004551 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.